



Australian Government

Department of Health

Therapeutic Goods Administration

Recall Action Notification

Elecsys CA 19-9 reagent for use on cobas e 801 analytical unit. An in vitro diagnostic medical device (IVD)

© Commonwealth of Australia 2021.

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <tga.copyright@tga.gov.au>.

Important information on the System for Australian Recall Actions

The TGA publishes information about therapeutic goods supplied in the Australian market that have been subject to a recall action in a publicly searchable database.

Recall action means action taken by the responsible entity (being the person who is responsible for taking the recall action) to resolve a problem with therapeutic goods supplied in the Australian market that have, or may potentially have, deficiencies relating to safety, quality, efficacy (performance) or presentation.

- Recall actions include: the permanent removal of therapeutic goods from supply in the market, the taking of corrective action in relation to therapeutic goods (such as repair, modification, adjustment or relabelling) and, in the case of medical devices that have been implanted into patients, the issuing of a hazard alert containing information for health practitioners on how to manage patients.
- More information about Australian recall actions is available at <<http://tga.gov.au/safety/recalls-about.htm>>
- If you are taking a medicine, using a medical device or have had a medical device implanted into you, that is the subject to a recall action, and you have any concerns you should seek advice from a health professional. <<http://www.healthdirect.org.au/>>

About the release of this information

While reasonable care is taken to ensure that the information is an accurate record of recall actions that responsible entities have reported to the TGA or of which the TGA has become aware, the TGA does not guarantee or warrant the accuracy, reliability, completeness or currency of the information or its usefulness in achieving any purpose.

To the fullest extent permitted by law, including but not limited to section 61A of the Therapeutic Goods Act 1989, the TGA will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on this information.

The information contained in the SARA database is released under s 61(5C) of the Therapeutic Goods Act 1989. Copyright restrictions apply to the System of Australian Recall actions (SARA) <<http://tga.gov.au/about/website-copyright.htm>>.

Recall detail

Type of Productⁱ	Medical Device
TGA Recall Referenceⁱⁱ	RC-2021-RN-01622-1
Product Name/Descriptionⁱⁱⁱ	<p>Elecsys CA 19-9 reagent for use on cobas e 801 analytical unit. An in vitro diagnostic medical device (IVD)</p> <p>Material number: 07027028190</p> <p>Lot number: 525510</p> <p>ARTG 174912 (Roche Diagnostics Australia Pty Limited - Clinical chemistry tumour marker IVDs)</p>
Recall Action Level^{iv}	Hospital
Recall Action Classification^v	Class II
Recall Action Commencement Date^{vi}	27/07/2021
Responsible Entity^{vii}	Roche Diagnostics Australia Pty Limited
Reason / Issue^{viii}	<p>Roche Diagnostics has previously advised of receiving an extremely small number of reports worldwide of non-reproducible elevated results in selected lots of Elecsys CA 19-9 E2G for use on the cobas e 801 analytical unit, with both serum and plasma samples.</p> <p>This recall notification is an update to RC-2020-RN-00097-1 to add a new Elecsys CA 19-9 affected lot number 525510 as Roche Diagnostics have now received this lot from the manufacturer.</p> <p>This issue can lead to non-reproducible elevated CA 19-9 results and therefore could affect clinical interpretation.</p>
Recall Action^{ix}	Product Defect Correction

Recall Action Instructions^x	<p>Roche Diagnostics is advising customers using the lot included in this recall action may continue to do so as long as the workaround described in the Customer Letter (supplied to impacted facilities) is taken into account.</p> <p>Customers are requested to not invert or shake the ePack prior to loading on the cobas e 801 analytical unit and to perform duplicate testing from the same tube for all results = 37 U/mL.</p> <p>Based on the most recent reports, customers are advised to perform double determinations from the same tube for all results = 37 U/mL CA 19-9 when using the reagent lot 525510 in order to allow the detection of possible non-reproducible elevated results (high flyers). Customers can still use the entire e-Pack and there is no need to restrict the number of determinations to the first 200.</p> <p>When a new unaffected lot becomes available, Roche Diagnostics will contact affected customers.</p>
Contact Information^{xi}	1800 645 619 - Roche Diagnostics Australia Technical Support

Footnotes

ⁱ Type of Product: Medicine, Medical Device, or Biological

ⁱⁱ TGA Recall Reference: Unique number given by the TGA

ⁱⁱⁱ Product Name/Description: Brand name (including active ingredient for medicines) and may include generic reference for the kind of medical devices. Includes all necessary information such as affected: catalogue / model and / or batch / serial numbers.

^{iv} Recall Action Level: The level to which the recall action is to be undertaken. This is based on the significance of the risk and the channels through which the goods have been distributed. The recall action levels are / Wholesale / Hospital / Retail / Consumer.

- **Wholesale** - includes wholesalers and state purchasing authorities.
- **Hospital** - includes nursing homes and institutions, hospital pharmacists, ambulance services, blood and tissue banks and laboratories as well as wholesale as appropriate.
- **Retail** - includes retail pharmacists, medical, dental and other health care professionals as well as wholesale and hospital as appropriate.
- **Consumer** - includes patients and consumers, as well as wholesale, hospital and retail levels as appropriate.

^v Recall Action Classification^{**}: Recall actions of therapeutic goods are classified based on the potential risk the deficiency poses to patients / consumers. They are classified as Class I, Class II or Class III.

- **Class I** - A situation in which there is a reasonable probability that the use of, or exposure to, the deficient therapeutic good(s) will cause serious adverse health consequences or death.
- **Class II** - A situation in which use of, or exposure to, the deficient therapeutic good(s) may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- **Class III** - A situation in which use of, or exposure to, the deficient therapeutic good(s) is not likely to cause adverse health consequences.

^{vi} Recall Action Commencement Date: The date the recall strategy and communication was agreed by the TGA.

^{vii} Responsible Entity: Sponsor / Supplier / Importer responsible for the recall actions.

^{viii} Reason / Issue: Reason for the recall action.

^{ix} Recall Action^{**}: Recall action is an action taken to resolve a problem with a therapeutic good already supplied in the market for which there are issues or deficiencies in relation to safety, quality, efficacy (performance) or presentation.

There are four distinct recall actions – recall, product defect correction, hazard alert and product defect alert.

- **Recall** - The permanent removal of an affected therapeutic good from supply or use in the market.
- **Product defect correction** - Repair, modification, adjustment or re-labelling of a therapeutic good. The corrective action may take place at the user's premises or any other agreed location.
- **Hazard alert** - Information issued to healthcare professionals about issues or deficiencies relating to an implanted medical device or biological product and advice about the ongoing management of patients.
- **Product defect alert** - Information issued to raise awareness about issues or deficiencies for a therapeutic good where a recall action will result in interruption of patient treatment or a medicine shortage, including advice to reduce potential risks of using affected goods.

^x Recall Action Instructions: What customers with affected goods should do.

^{xi} Contact Information: Who the customer should contact for additional information and clarification regarding the recall action.

^{**} These definitions are applicable to the 2017 URPTG (Implemented from Jan 15 2018). Recall Action types and Recall Action Classifications prior to 15 Jan 2018 can be found at:

<https://www.tga.gov.au/sites/default/files/recalls-urptg-170412.pdf>